NEW YORK (GenomeWeb) – Signal Genetics said in a regulatory document on Wednesday that it has reached agreements to exclusively provide gene array clinical genetic testing services to the University of Arkansas for Medical Sciences.
The New York City-based firm signed a reference laboratory services agreement with the board of trustees of the University of Arkansas on behalf of UAMS, Signal said in a document filed with the US Securities and Exchange Commission. It also reached a reference laboratory services agreement for research specimens to be the exclusive provider of gene array clinical genetic testing services for research purposes to UAMS.
Both agreements were entered into on Sept. 19 and remain in effect until Sept. 19, 2017. They can be renewed after the end of the initial term by Signal and UAMS for additional 12-month terms. Financial and other terms of the agreements were not disclosed.
The deals renew and extend Signal's current reference laboratory services agreement and reference laboratory services agreement for research specimens with UAMS, dated March 21, 2011, Signal said.